2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 279

Distribution of Vasculitides in Childhood Arthritis and Rheumatology Research Alliance-Affiliated Pediatric Rheumatology Centers in the United States
Abstract Number: 492

Divergent Toxicity of TNF Inhibitors On Demyelinating Disorders and Neurological Events
Abstract Number: 593

DKK1 Serum Level Is Increased in Recent Spondyloarthritis and Is Associated with Higher Prevalence of Syndesmophytes. Sclerostin Is Highly Correlated with Age. Data From the DESIR Cohort
Abstract Number: 380

DMARD and Biologic Use During Pregnancy Among Rheumatoid and Psoriatic Arthritis Patients in the Corrona Registry
Abstract Number: 2611

Do Patients with Psoriatic Arthritis Fall Into Distinct Clinical Sub-Groups- a Cluster Analysis?
Abstract Number: 840

Do Serum Hepcidin 25 Levels Predict SLE Renal or Non-Renal Flares?
Abstract Number: 1824

Do Statins Reduce the Incidence of Connective Tissue Disease? A Retrospective Cohort Study
Abstract Number: 2004

Do We Need a Minimum Standards in Care for Children with Localized Scleroderma- Result of the Consensus Meeting in Hamburg Germany On the 11th of December 2011. Part I. Diagnosis and Assessment of the Disease
Abstract Number: 1087

Do Younger TKR Patients Have Similar Disability At Time of Surgery As Older Adults?
Abstract Number: 2043

Documentation of Improvement Over 2 Months in Osteoarthritis, Systemic Lupus Erythematosus, Spondyloarthropathy and Gout Similarly to Rheumatoid Arthritis According to Function, Pain, Patient Global Estimate and RAPID3 On a Multidimensional Health Assessment Questionnaire (MDHAQ)
Abstract Number: 382

Does Biased Risk Perception Explain the Underuse of Disease Modifying Anti-Rheumatic Drugs?
Abstract Number: 2009

Does Breastfeeding Influence the Presentation of Juvenile Idiopathic Arthritis? Results From the Childhood Arthritis Prospective Study
Abstract Number: 2415

Does Interleukin-6 Mediate the Relation Between Estrogen and Bone? an Epidemiologic Approach in the Framingham Osteoporosis Study
Abstract Number: 109

Does Joint Sonography Really Add Clinically Important Information Beyond Clinical Joint Examination?
Abstract Number: 1541

Does Leflunomide Have a Place As Remission Maintenance Therapy in ANCA-Associated Vasculitis? A Bayesian Network Meta-Analysis with Hypothesis Driven Sensitivity Analyses to Adjust for Potential Biases

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].